Future treatment strategies for celiac disease

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 7, 2012, Pages 665-675

  Lindfors, Katri ^a   Lähdeaho, Marja Leena ^a   Kalliokoski, Suvi ^a   Kurppa, Kalle ^a   Collin, Pekka ^a,b   Mäki, Markku ^a   Kaukinen, Katri ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

celiac disease; drug; gluten; gluten free diet; small bowel; treatment

Indexed keywords

2 HYDROXYETHYL METHACRYLATE; ADALIMUMAB; ALV 003; CERTOLIZUMAB PEGOL; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR9 ANTAGONIST; CYSTEINE PROTEINASE; GLIADIN; GLUTEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; INFLIXIMAB; LARAZOTIDE; NATALIZUMAB; POLYSTYRENESULFONATE SODIUM; PROBIOTIC AGENT; PROLAMIN; PROLYL ENDOPEPTIDASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; UNCLASSIFIED DRUG; VEDOLIZUMAB;

CELIAC DISEASE; DETOXIFICATION; DISEASE ACTIVITY; DISEASE MARKER; DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; ENZYME THERAPY; GLUTEN FREE DIET; HUMAN; INFLAMMATION; INTESTINE CRYPT; INTESTINE INJURY; INTESTINE VILLUS ATROPHY; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SEROLOGY; TREATMENT OUTCOME; WHEAT;

ANIMALS; CELIAC DISEASE; DIET; DIET, GLUTEN-FREE; GLUTENS; HUMANS; SERINE ENDOPEPTIDASES;

EID: 84862532135     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.688808     Document Type: Review

References (101)

1. Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut 2012;doi: gutjnl-2011-301346
2. Mustalahti K, Catassi C, Reunanen A, et al. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med 2010;42:587-95
3. Kaukinen K, Lindfors K, Collin P, et al. Coeliac disease - a diagnostic and therapeutic challenge. Clin Chem Lab Med 2010;48:1205-16
4. Haines ML, Anderson RP, Gibson PR. Systematic review: the evidence base for long-term management of coeliac disease. Aliment Pharmacol Ther 2008;28:1042-66
5. Sollid LM, Khosla C. Novel therapies for coeliac disease. J Intern Med 2011;269:604-13
6. Wieser H. Chemistry of gluten proteins. Food Microbiol 2007;24:115-19 (Pubitemid 44428081)
7. Kasarda DD. Gluten and gliadin: Precipitating factors in coeliac disease. In: Maki M, Collin P, Visakorpi JK, editors. Coeliac Disease. Coeliac Disease Study Group; Tampere: 1997. p. 195-212
8. Galili G, Altschuler Y, Levanony H. Assembly and transport of seed storage proteins. Trends Cell Biol 1993;3:437-42 (Pubitemid 23352088)
9. Shewry P, Tatham A, Kasarda D. Cereal proteins and coeliac disease. In: Marsh M, editor. Coeliac Disease. Blackwell Scientific Publications; Oxford: 1992. p. 305-48
10. Jones B. Endoproteases of barley and malt. J Cereal Sci 2005;42:139-56 (Pubitemid 40938559)
11. Bottari A, Capocchi A, Fontanini D, et al. Major proteinase hydrolyzing gliadin during wheat germination. Phytochemistry 1996;43:39-44 (Pubitemid 27065587)
12. Laitila A, Kotoviita E, Peltola P, et al. Indigenous microbial community of barley greatly influences grain germination and mal quality. J Inst Brew 2007;113:9-20
13. Hausch F, Shan L, Santiago NA, et al. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002;283:G996-G1003 (Pubitemid 35033943)
14. Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science 2002;297:2275-9 This study shows that prolyl endopeptidase can detoxify an immuno-dominant gliadin peptide and thus suggest that oral peptidase supplementation therapy could be useful in celiac disease.
15. Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther 2007;26:1217-25 (Pubitemid 47620425)
16. Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increase prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009;137:88-93
17. Karell K, Louka AS, Moodie SJ, et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European genetics cluster on celiac disease. Hum Immunol 2003;64:469-77 (Pubitemid 36373778)
18. van Heel DA, Franke L, Hunt KA, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007;39:827-9 (Pubitemid 47014494)
19. Dubois PC, Trynka G, Franke L, et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010;42:295-302
20. Kurppa K, Collin P, Viljamaa M, et al. Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study. Gastroenterology 2009;136:816-23
21. Husby S, Koletzko S, Korponay-Szabo IR, et al. European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012;54:136-60
22. Lundin KE, Scott H, Hansen T, et al. Gliadin-specific, HLA-DQ(alpha 1*0501, beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 1993;178:187-96 (Pubitemid 23173254)
23. Molberg O, Mcadam SN, Korner R, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998;4:713-17 This study shows the importance of TG2 in the pathogenesis of celiac disease and gives the rational for TG2 inhibition as a future therapeutic strategy. (Pubitemid 28274673)
24. Abadie V, Sollid LM, Barreiro LB, et al. Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annu Rev Immunol 2011;29:493-525
25. Jabri B, Patey-Mariaud de Serre N, Gache C, et al. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 2000;118:867-9
26. Maiuri L, Ciacci C, Ricciardelli I, et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003;362:30-7 (Pubitemid 36835817)
27. Hue S, Mention JJ, Monteiro RC, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004;21:367-77 (Pubitemid 39208338)
28. Barone MV, Gimigliano A, Castoria G, et al. Growth factor-like activity of gliadin, an alimentary protein: implications for coeliac disease. Gut 2007;56:480-8 (Pubitemid 46580502)
29. Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997;3:797-801 (Pubitemid 27298728)
30. Lindfors K, Maki M, Kaukinen K. Transglutaminase 2-targeted autoantibodies in celiac disease: pathogenetic players in addition todiagnostic tools? Autoimmun Rev 2010;9:744-9
31. Stene LC, Honeyman MC, Hoffenberg EJ, et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 2006;101:2333-40 (Pubitemid 44477562)
32. Ivarsson A, Persson LA, Nystrom L, et al. Epidemic of coeliac disease in Swedish children. Acta Paediatr 2000;89:165-71 (Pubitemid 30339587)
33. Hischenhuber C, Crevel R, Jarry B, et al. Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease. Aliment Pharmacol Ther 2006;23:559-75
34. Kaukinen K, Collin P, Holm K, et al. Wheat starch-containing gluten-free flour products in the treatment of coeliac disease and dermatitis herpetiformis. A long-term follow-up study. Scand J Gastroenterol 1999;34:164-9
35. Hallert C, Granno C, Hulten S, et al. Living with coeliac disease: controlled study of the burden of illness. Scand J Gastroenterol 2002;37:39-42 (Pubitemid 34074732)
36. Fabiani E, Taccari LM, Ratsch I-M, et al. Compliance with gluten-free diet in adolescents with screening-detected celiac disease: a 5-year follow-up study. J Pediatr 2000;136:841-3 (Pubitemid 30415665)
37. Hall NJ, Rubin G, Charnock A. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009;30:315-30
38. Wild D, Robins GG, Burley VJ, et al. Evidence of high sugar intake, and low fibre and mineral intake, in the gluten-free diet. Aliment Pharmacol Ther 2010;32:573-81
39. Gass J, Khosla C. Prolyl endopeptidases. Cell Mol Life Sci 2007;64:345-55 (Pubitemid 46440200)
40. Garcia-Horsman JA, Venalainen JI, Lohi O, et al. Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease. Scand J Gastroenterol 2007;42:562-71 (Pubitemid 46633808)
41. Stepniak D, Spaenij-Dekking L, Mitea C, et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 2006;291:G621-9 (Pubitemid 44511679)
42. Mitea C, Havenaar R, Drijfhout JW, et al. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 2008;57:25-32 This study demonstares the efficacy of endopeptidase to digest gluten in a gastrointestinal model.
43. Piper JL, Gray GM, Khosla C. Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo. J Pharmacol Exp Ther 2004;311:213-19 (Pubitemid 39287800)
44. Shan L, Marti T, Sollid LM, et al. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J 2004;383:311-18 (Pubitemid 39446692)
45. Marti T, Molberg O, Li Q, et al. Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J Pharmacol Exp Ther 2005;312:19-26 (Pubitemid 40096448)
46. Pyle GG, Paaso B, Anderson BE, et al. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin Gastroenterol Hepatol 2005;3:687-94 (Pubitemid 40984730)
47. Bethune MT, Strop P, Tang Y, et al. Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease. Chem Biol 2006;13:637-47 (Pubitemid 43949134)
48. Gass J, Vora H, Bethune MT, et al. Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat. J Pharmacol Exp Ther 2006;318:1178-86 (Pubitemid 44268324)
49. Bethune MT, Borda JT, Ribka E, et al. A non-human primate model for gluten sensitivity. PLoS One 2008;3:e1614
50. Gass J, Bethune MT, Siegel M, et al. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007;133:472-80 This study descibes the efficacy of enzyme combination therapy to treat celiac disease. (Pubitemid 47187353)
51. Siegel M, Bethune MT, Gass J, et al. Rational design of combination enzyme therapy for celiac sprue. Chem Biol 2006;13:649-58
52. Tye-Din JA, Anderson RP, Ffrench RA, et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol 2010;134:289-95
53. Siegel M, Garber ME, Spencer AG, et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci 2012;57:440-50
54. Lahdeaho M-L, Kaukinen K, Laurila K, et al. ALV003, a novel glutanase, attenuates gluten-induced small intestinal mucosal injury in coeliac disease patients: a randomized controlled Phase 2a clinical trial. Gut 2011;60:A12 This preliminary study reports the findings made in a clinical trial to that glutanase is able to prevent gluten-induced small-bowel damage.
55. Stenman S, Venalainen JI, Lindfors K, et al. Enzymatic detoxification of gluten by germinating wheat proteases: implications for new treatment of celiac disease. Ann Med 2009;41:390-400
56. Stenman S, Lindfors K, Venalainen JI, et al. Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells. Clin Exp Immunol 2010;161:242-9
57. Zamakhchari M, Wei G, Dewhirst F, et al. Identification of Rothia bacteria as gluten-degrading natural colonizers of the upper gastro-intestinal tract. PLoS One 2011;6:e24455
58. Forsberg G, Fahlgren A, Horstedt P, et al. Presence of bacteria and innate immunity of intestinal epithelium in childhood celiac disease. Am J Gastroenterol 2004;99:894-904 (Pubitemid 39090220)
59. Nistal E, Caminero A, Herran AR, et al. Differences of small intestinal bacteria populations in adults and children with/without celiac disease: effect of age, gluten diet, and disease. Inflamm Bowel Dis 2012;18:649-56
60. De Palma G, Nadal I, Medina M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol 2010;10:63
61. Sanchez E, Donat E, Ribes-Koninckx C, et al. Intestinal Bacteroides species associated with coeliac disease. J Clin Pathol 2010;63:1105-11
62. Lindfors K, Blomqvist T, Juuti-Uusitalo K, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol 2008;152:552-8 (Pubitemid 351661494)
63. Cinova J, De Palma G, Stepankova R, et al. Role of intestinal bacteria in gliadin-induced changes in intestinal mucosa: study in germ-free rats. PLoS One 2011;6:e16169
64. Liang L, Pinier M, Leroux JC, et al. Interaction of alpha-gliadin with poly (HEMA-co-SS): structural characterization and biological implication. Biopolymers 2009;91:169-78
65. Pinier M, Verdu EF, Nasser-Eddine M, et al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 2009;136:288-98 This is the first study performed with polymeric binders to supress gliadin-induced damage.
66. Pinier M, Fuhrmann G, Galipeau H, et al. The copolymer P(HEMA)-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 2012;142:316-25
67. Spaenij-Dekking L, Kooy-Winkelaar Y, van Veelen P, et al. Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology 2005;129:797-806 (Pubitemid 41242672)
68. Tripathi A, Lammers KM, Goldblum S, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci 2009;106:16799-804
69. Fasano A, Not T, Wang W, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000;355:1518-19 (Pubitemid 30237361)
70. Drago S, El Asmar R, Di Pierro M, et al. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006;41:408-19 (Pubitemid 43675406)
71. Wang W, Uzzau S, Goldblum SE, et al. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci 2000;113:4435-40 (Pubitemid 32117904)
72. Di Pierro M, Lu R, Uzzau S, et al. Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J Biol Chem 2001;276:19160-5
73. Clemente MG, De Virgiliis S, Kang JS, et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 2003;52:218-23 (Pubitemid 36115062)
74. Silva MA, Jury J, Sanz Y, et al. Increased bacterial translocation in gluten-sensitive mice is independent of small intestinal paracellular permeability defect. Dig Dis Sci 2012;57:38-47
75. Paterson BM, Lammers KM, Arrieta MC, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007;26:757-66 (Pubitemid 47246202)
76. Cassani B, Villablanca EJ, Quintana FJ, et al. Gut-tropic T cells that express integrin alpha4beta7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology 2011;141:2109-18
77. Wermers JD, McNamee EN, Wurbel MA, et al. The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice. Gastroenterology 2011;140:1526-35
78. Wurbel MA, McIntire MG, Dwyer P, et al. CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PLoS One 2011;6:e16442
79. Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 2010;6:149-57
80. Sandborn WJ, Colombel JF, Frankel M, et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 2010;59:1485-92
81. Gillett HR, Arnott ID, McIntyre M, et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 2002;122:800-5 (Pubitemid 34173833)
82. Yokoyama S, Watanabe N, Sato N, et al. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci 2009;106:15849-54
83. Simon-Vecsei Z, Kiraly R, Bagossi P, et al. A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects. Proc Natl Acad Sci 2012;109:431-6
84. Molberg O, McAdam S, Lundin KEA, et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol 2001;31:1317-23 (Pubitemid 32454680)
85. Maiuri L, Ciacci C, Ricciardelli I, et al. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 2005;129:1400-13 (Pubitemid 41597382)
86. Lindfors K, Rauhavirta T, Kivisto R, et al. Are TG2 inhibitors able to decrease gliadin-induced toxicity related to celiac disease - a proof of concept study. J Pediatr Gastroenterol Nutr 2011;52:E6
87. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 2008;205:143-54 (Pubitemid 351185722)
88. Xia J, Bergseng E, Fleckenstein B, et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg Med Chem 2007;15:6565-73 (Pubitemid 47302312)
89. Kapoerchan VV, Wiesner M, Overhand M, et al. Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with celiac disease. Bioorg Med Chem 2008;16:2053-62 (Pubitemid 351226566)
90. Kapoerchan VV, Wiesner M, Hillaert U, et al. Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule. Mol Immunol 2010;47:1091-7
91. Juse U, van de Wal Y, Koning F, et al. Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library. Hum Immunol 2010;71:475-81
92. Arentz-Hansen H, Korner R, Molberg O, et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000;191:603-12
93. Tye-Din JA, Stewart JA, Dromey JA, et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med 2010;2:41ra51 This study reports the identification of peptides inducing a T-cell response in celiac patients and thus sets the basis for celiac disease vaccination.
94. Verhoef A, Alexander C, Kay AB, et al. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005;2:e78
95. Hmida NB, Ben Ahmed M, Moussa A, et al. Impaired control of effector T cells by regulatory T cells: a clue to loss of oral tolerance and autoimmunity in celiac disease? Am J Gastroenterol 2012;1007:604-11
96. Aoyama H, Hirata T, Sakugawa H, et al. An inverse relationship between autoimmune liver diseases and Strongyloides stercoralis infection. Am J Trop Med Hyg 2007;76:972-6 (Pubitemid 351627689)
97. Elliott DE, Weinstock JV. Helminthic therapy: using worms to treat immune-mediated disease. Adv Exp Med Biol 2009;666:157-66
98. Daveson AJ, Jones DM, Gaze S, et al. Effect of hookworm infection on wheat challenge in celiac disease - a randomised double-blinded placebo controlled trial. PLoS One 2011;6:e17366
99. McSorley HJ, Gaze S, Daveson J, et al. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS One 2011;6:e24092
100. Aziz I, Evans KE, Papageorgiou V, et al. Are patients with coeliac disease seeking alternative therapies to a gluten-free diet? J Gastrointestin Liver Dis 2011;20:27-31
101. Crespo Perez L, Leon F. Clinical trial data provides hope for attenuation of mucosal injury in coeliac disease. Eur J Intern Med 2012;23:9-14